VistaGen Therapeutics

VistaGen Therapeutics Overview

Founded 1998
Status Public
Employees 9
Stock Symbol VTGN
Stock Symbol
Investments 1
Share Price $0.45 (As of Thursday Closing)

VistaGen Therapeutics General Information


VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants.

Contact Information

Ownership Status
Publicly Held
Financing Status
Primary Industry
Other Industries
Drug Discovery
Stock Exchange
Primary Office
  • 343 Allerton Avenue
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

VistaGen Therapeutics Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.45 $0.45 $0.29 - $1.49 $22.5M 49.9M 620K -$0.58

VistaGen Therapeutics Financials Summary

In Thousands,
TTM 31-Dec-2019 FY 2019 31-Mar-2019 FY 2018 31-Mar-2018 FY 2017 31-Mar-2017
EV 30,079 46,412 8,280 12,489
Revenue 0 0 0 1,250
EBITDA (23,156) (24,488) (14,254) (10,194)
Net Income (23,231) (24,590) (14,346) (10,256)
Total Assets 5,331 14,012 11,278 3,712
Total Debt 4,177 67 66 69
Public Fundamental Data provided by Morningstar, Inc. disclaimer

VistaGen Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore VistaGen Therapeutics‘s full profile, request access.

Request a free trial

VistaGen Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Shawn Singh JD Chief Executive Officer & Board Member
Ralph Snodgrass Director, President & Chief Scientific Officer & Co-Founder
Jerrold Dotson Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
H. Snodgrass Chief Scientific Officer & Board Member
Gordon Keller Co-Founder

VistaGen Therapeutics Board Members (4)

Name Representing Role Since
00000 000000000 00.0 VistaGen Therapeutics Director 000 0000
0. 000000000 VistaGen Therapeutics Chief Scientific Officer & Board Member 000 0000
0000 0000 00 Self Chairman 000 0000
00000 00000 00 VistaGen Therapeutics Chief Executive Officer & Board Member 000 0000

VistaGen Therapeutics Acquisitions (1)

To view VistaGen Therapeutics‘s complete investment and acquisition history, request access »
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 11-May-2011 000000000000000000 Other Consumer Products and Services 00000 00000 00

Ready to get started?

Request a free trial